INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Pathologic confirmation of lung adenocarcinoma     │ Pathologic confirmation of lung adenocarcinoma     │     100 │
│ with measurable disease, defined as at least one   │ with measurable disease, defined as at least one   │         │
│ lesion that can be accurately measured in at least │ lesion that can be accurately measured in at least │         │
│ one dimension (longest diameter to be recorded on  │ one dimension (longest diameter to be recorded on  │         │
│ CT); Patients must have previously untreated       │ CT); Patients must have previously untreated       │         │
│ locally advanced or metastatic NSCLC; Patients     │ locally advanced or metastatic NSCLC; Patients     │         │
│ must have lung cancer with a documented EGFR       │ must have lung cancer with a documented EGFR       │         │
│ activating mutation (exon 19 deletion, L858R)      │ activating mutation (exon 19 deletion, L858R)      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior chemotherapy Prior treatment with gefitinib, │ Prior chemotherapy Prior treatment with gefitinib, │     100 │
│ erlotinib, or other drugs that target EGFR         │ erlotinib, or other drugs that target EGFR         │         │
│ Patients must not be receiving any other           │ Patients must not be receiving any other           │         │
│ investigational agents Any evidence of             │ investigational agents Any evidence of             │         │
│ interstitial lung disease                          │ interstitial lung disease                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Prior chemotherapy Prior treatment with gefitinib, │      20 │
│                                   │ erlotinib, or other drugs that target EGFR         │         │
│                                   │ Patients must not be receiving any other           │         │
│                                   │ investigational agents Any evidence of             │         │
│                                   │ interstitial lung disease                          │         │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 70 Years │ Prior chemotherapy Prior treatment with gefitinib, │      20 │
│                                   │ erlotinib, or other drugs that target EGFR         │         │
│                                   │ Patients must not be receiving any other           │         │
│                                   │ investigational agents Any evidence of             │         │
│                                   │ interstitial lung disease                          │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 94
Average Levenshtein Ratio of individual lines: 60.0
OverAll Ratio: 77.0
